Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giorgia Guaitoli
Observed names:
G. Guaitoli,
Guaitoli Giorgia,
Guaitoli, Giorgia
Institutions:
University of Modena and Reggio Emilia,
Azienda Ospedaliero-Universitaria di Modena
Observed institutions:
University of Modena and Reggio Emilia,
Inserm,
Université Paris-Saclay,
Institut Gustave Roussy,
Azienda Ospedaliero-Universitaria di Modena,
Prédicteurs moléculaires et nouvelles cibles en oncologie
show all 6
ORCID:
0000-0001-8671-9910
Observed ORCID:
0000-0001-8671-9910
OpenAlex ID:
A5048627770
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
2021
·
Alessio Cortellini
, Massimo Di Maio
, et al.
·
Journal for ImmunoTherapy of Cancer
·
171
PDF
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
2022
·
Beatrice Aramini
, Valentina Masciale
, et al.
·
Cancers
·
167
PDF
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
2020
·
Francesco Facchinetti
, Giulia Mazzaschi
, et al.
·
European Journal of Cancer
·
153
PDF
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
2020
·
Alessio Cortellini
, Biagio Ricciuti
, et al.
·
Journal for ImmunoTherapy of Cancer
·
109
PDF
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
2020
·
Alessio Cortellini
, Marcello Tiseo
, et al.
·
Cancer Immunology Immunotherapy
·
104
PDF
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
2021
·
Anna Valeria Samarelli
, Valentina Masciale
, et al.
·
International Journal of Molecular Sciences
·
99
PDF
Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer
2023
·
Francesco Facchinetti
, Antoine Hollebecque
, et al.
·
Cancer Discovery
·
96
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020
·
Alessio Cortellini
, Alex Friedlaender
, et al.
·
Clinical Lung Cancer
·
93
PDF
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
2018
·
Claudia Omarini
, Giorgia Guaitoli
, et al.
·
Cancer Management and Research
·
80
PDF
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021
·
G.L. Banna
, A. Cortellini
, et al.
·
ESMO Open
·
66
PDF
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
2016
·
C. Omarini
, G. Guaitoli
, et al.
·
European Journal of Surgical Oncology
·
66
Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
2021
·
Cinzia Baldessari
, Giorgia Guaitoli
, et al.
·
Clinical Nutrition ESPEN
·
46
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
2021
·
Giorgia Guaitoli
, Marcello Tiseo
, et al.
·
Translational Lung Cancer Research
·
40
PDF
Non-small-cell lung cancer: how to manage BRAF-mutated disease
2023
·
Giorgia Guaitoli
, Lodovica Zullo
, et al.
·
Drugs in Context
·
37
PDF
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
2021
·
Sebastiano Buti
, Melissa Bersanelli
, et al.
·
European Journal of Cancer
·
37
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study
2020
·
Roberta Minari
, Giulia Mazzaschi
, et al.
·
Clinical Lung Cancer
·
31
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
2018
·
Claudia Omarini
, Stefania Bettelli
, et al.
·
Cancer Biology & Therapy
·
30
PDF
Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
2021
·
Giorgia Guaitoli
, Federica Bertolini
, et al.
·
International Journal of Molecular Sciences
·
25
PDF
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023
·
Melissa Bersanelli
, Elena Verzoni
, et al.
·
EClinicalMedicine
·
24
PDF
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
2021
·
Melissa Bersanelli
, Diana Giannarelli
, et al.
·
Journal for ImmunoTherapy of Cancer
·
24
PDF
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017
·
M.E. Cazzaniga
, M. Airoldi
, et al.
·
The Breast
·
23
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma
2019
·
Lorena Losi
, Federica Bertolini
, et al.
·
International Journal of Oncology
·
22
PDF
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
2022
·
Fabiana Perrone
, Giulia Mazzaschi
, et al.
·
Cancers
·
19
PDF
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024
·
Alessandro Leonetti
, Fabiana Perrone
, et al.
·
European Journal of Cancer
·
17
PDF
Treating cancer with immunotherapy in HIV-positive patients: A challenging reality
2019
·
Giorgia Guaitoli
, Cinzia Baldessari
, et al.
·
Critical Reviews in Oncology/Hematology
·
17
Show more works
View as search
Works count:
146
Citation count:
1,753
H-index:
22
I10-index:
31
Year
Topic
Type